NEW YORK, Nov. 14 – Orchid BioSciences said Wednesday it had agreed to collaborate with GlaxoSmithKline on a genome-wide SNP-validation program.

Under the terms of the deal, Glaxo will select SNP candidates from Orchid’s database and Orchid will provide high-throughput genotyping information. In addition, Orchid will also develop SNP assays for use in the genome-wide study. 

Financial terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.